Cargando…

How to Manage a Patient with Ocular Metastases?

Ocular metastases are the most frequent ocular malignant tumors; their prevalence is estimated around 5–10% and is even higher in patients with breast or lung cancer. They represent various clinical situations, but they share the same hierarchical multidisciplinary therapeutic challenge with respect...

Descripción completa

Detalles Bibliográficos
Autores principales: Thariat, Juliette, Boudin, Laurys, Loria, Olivier, Nguyen, Anh-Minh, Kodjikian, Laurent, Mathis, Thibaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775125/
https://www.ncbi.nlm.nih.gov/pubmed/36551800
http://dx.doi.org/10.3390/biomedicines10123044
_version_ 1784855567296102400
author Thariat, Juliette
Boudin, Laurys
Loria, Olivier
Nguyen, Anh-Minh
Kodjikian, Laurent
Mathis, Thibaud
author_facet Thariat, Juliette
Boudin, Laurys
Loria, Olivier
Nguyen, Anh-Minh
Kodjikian, Laurent
Mathis, Thibaud
author_sort Thariat, Juliette
collection PubMed
description Ocular metastases are the most frequent ocular malignant tumors; their prevalence is estimated around 5–10% and is even higher in patients with breast or lung cancer. They represent various clinical situations, but they share the same hierarchical multidisciplinary therapeutic challenge with respect to the way systemic and local therapies should be selected in combination or sequentially in the personalized medical history of a patient. The challenges include tumor control, eye preservation, and the minimization of iatrogenic damage to sensitive tissues surrounding the tumor in order to preserve vision. These aims should further contribute to maintaining quality of life in patients with metastases. Many patients with choroidal metastases have systemic molecular treatment for their primary tumor. However, secondary resistance to systemic treatment is common and may ultimately be associated with cancer relapse, even after an initial response. Therefore, it makes sense to propose local treatment concomitantly or after systemic therapy to provide a more sustainable response. The aim of this review is to present current therapeutic strategies in ocular metastases and discuss how to tailor the treatment to a specific patient.
format Online
Article
Text
id pubmed-9775125
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97751252022-12-23 How to Manage a Patient with Ocular Metastases? Thariat, Juliette Boudin, Laurys Loria, Olivier Nguyen, Anh-Minh Kodjikian, Laurent Mathis, Thibaud Biomedicines Review Ocular metastases are the most frequent ocular malignant tumors; their prevalence is estimated around 5–10% and is even higher in patients with breast or lung cancer. They represent various clinical situations, but they share the same hierarchical multidisciplinary therapeutic challenge with respect to the way systemic and local therapies should be selected in combination or sequentially in the personalized medical history of a patient. The challenges include tumor control, eye preservation, and the minimization of iatrogenic damage to sensitive tissues surrounding the tumor in order to preserve vision. These aims should further contribute to maintaining quality of life in patients with metastases. Many patients with choroidal metastases have systemic molecular treatment for their primary tumor. However, secondary resistance to systemic treatment is common and may ultimately be associated with cancer relapse, even after an initial response. Therefore, it makes sense to propose local treatment concomitantly or after systemic therapy to provide a more sustainable response. The aim of this review is to present current therapeutic strategies in ocular metastases and discuss how to tailor the treatment to a specific patient. MDPI 2022-11-25 /pmc/articles/PMC9775125/ /pubmed/36551800 http://dx.doi.org/10.3390/biomedicines10123044 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Thariat, Juliette
Boudin, Laurys
Loria, Olivier
Nguyen, Anh-Minh
Kodjikian, Laurent
Mathis, Thibaud
How to Manage a Patient with Ocular Metastases?
title How to Manage a Patient with Ocular Metastases?
title_full How to Manage a Patient with Ocular Metastases?
title_fullStr How to Manage a Patient with Ocular Metastases?
title_full_unstemmed How to Manage a Patient with Ocular Metastases?
title_short How to Manage a Patient with Ocular Metastases?
title_sort how to manage a patient with ocular metastases?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775125/
https://www.ncbi.nlm.nih.gov/pubmed/36551800
http://dx.doi.org/10.3390/biomedicines10123044
work_keys_str_mv AT thariatjuliette howtomanageapatientwithocularmetastases
AT boudinlaurys howtomanageapatientwithocularmetastases
AT loriaolivier howtomanageapatientwithocularmetastases
AT nguyenanhminh howtomanageapatientwithocularmetastases
AT kodjikianlaurent howtomanageapatientwithocularmetastases
AT mathisthibaud howtomanageapatientwithocularmetastases